Synaptogenix has filed a notice of an exempt offering of securities to raise $3,207,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Synaptogenix is raising up to $3,207,000.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Robert Weinstein played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Synaptogenix
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders. Our experience and passion for novel drug therapies have enabled us to develop a pipeline that includes synaptogenic treatment approaches for serious and difficult-to-treat diseases such as Alzheimer’s disease, Fragile X Syndrome, MS, Parkinsons, Traumatic Brain Injury, Stroke, and Autism Spectrum Disorders.
To learn more about Synaptogenix, visit http://www.synaptogen.com/
Synaptogenix Linkedin Page: https://www.linkedin.com/company/synaptogenix-inc/
Contact:
Robert Weinstein, Chief Financial Officer
973-242-0005
https://www.linkedin.com/in/robert-weinstein-08a7a087/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.